The people deciding what AI means for biopharma

Wednesday, October 14, 2026 | Georgia Room, NYC | Hybrid

Anthropic's head of drug discovery research. Recursion's CEO. Takeda's head of AI and data. AI Day puts them in the room together on Oct. 14 in NYC.

The first AI-designed drugs are reaching the clinic and record money is going in. What comes back out is still unsettled. Endpoints Senior Biopharma Correspondent Andrew Dunn hosts a day of sessions with the researchers, executives and investors who will decide it.

Join us in New York for exclusive discussions that keep going over an open bar and heavy hors d'oeuvres. Or tune in to the free virtual program.

SELECT YOUR PASS

Save $100 as an NYC local with code AIDAY100
Can't make it to the Georgia Room? Reserve your virtual pass

Be in the room with:

Nathan Frey, head of drug discovery and development research at Anthropic
Sydney Klein, chief information security officer at Bristol Myers Squibb
Subbu Iyer, head of AI and data at Takeda
Najat Khan, CEO and president of Recursion (in-person exclusive)
Zavain Dar, founder and managing partner at Dimension (in-person exclusive)
and more

Nathan Frey, Anthropic

Limited in-person spots available.

After virtual morning sessions with:

David Baker, director of the Institute for Protein Design at the University of Washington
Travis Zack, chief medical officer at OpenEvidence
Melissa J. Moore, co-founder of Kerna Labs and Waterfall Scientific
and more

SELECT YOUR PASS

Save $100 as an NYC local with code AIDAY100
Can't make it to the Georgia Room? Reserve your virtual pass